Evidence map›Paper›PMID 35059607›Full record

ArticleiScience2022

Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease.

Katharina Hopp, Victoria A Catenacci, Nidhi Dwivedi, Timothy L Kline, Wei Wang, Zhiying You, Dustin T Nguyen, Kristen Bing, Bhavya Poudyal, Ginger C Johnson and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Trial
  3. Trial
  4. Trial
  5. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  6. Review
  7. Review
  8. SGLT2 inhibition for patients with ADPKD - closing the evidence gap.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  9. Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.Current opinion in nephrology and hypertension · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Katharina HoppDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Victoria A CatenacciDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Nidhi DwivediDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Timothy L KlineDepartment of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA.
Wei WangDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Zhiying YouDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Dustin T NguyenDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Kristen BingDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Bhavya PoudyalDepartment of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA.
Ginger C JohnsonDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Matthew R JackmanDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Marsha MillerDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Cortney N SteeleDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Natalie J SerkovaDepartment of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Paul S MacLeanDepartment of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Raphael A NemenoffDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Berenice GitomerDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Michel ChoncholDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Kristen L NowakDepartment of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
University of Colorado Anschutz Medical Campus · USMayo Clinic · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
Research BaseP30DK090868 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI WATNICK, TERRY J · 2010 to 2019
$11.1M
TRAINING IN RENAL &ELECTROLYTE DISEASE &HYPERTENSIONT32DK007135 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JOHNSON, RICHARD JOSEPH, KENDRICK, JESSICA B · 1986 to 2024
$5.3M
3T MRIS10OD018435 · OD · UNIVERSITY OF COLORADO DENVER · PI TREGELLAS, JASON R · 2014 to 2014
$2.0M
Bruker 9.4T/ 20cm BioSpec MR Scanner for Colorado Animal Imaging Shared ResourcesS10OD023485 · OD · UNIVERSITY OF COLORADO DENVER · PI SERKOVA, NATALIE J. · 2017 to 2017
$2.0M
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathologyK01DK114164 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HOPP, KATHARINA · 2018 to 2022
$783k
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKDK01DK103678 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NOWAK, KRISTEN LYNN · 2015 to 2019
$758k
Complement as a modulator of immunosuppression and progression in Polycystic Kidney DiseaseR03DK129414 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HOPP, KATHARINA · 2021 to 2022
$233k
Daily caloric restriction and intermittent fasting in overweight and obese adults with autosomal dominant polycystic kidney diseaseR03DK118215 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NOWAK, KRISTEN LYNN · 2018 to 2019
$233k
NCATS NIH HHS UL1 TR002535NCI NIH HHS P30 CA046934NCRR NIH HHS UL1 RR025780NIDDK NIH HHS K01 DK103678NIDDK NIH HHS K01 DK114164NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK090868NIDDK NIH HHS R03 DK118215NIDDK NIH HHS R03 DK129414NIDDK NIH HHS T32 DK007135NIH HHS S10 OD018435NIH HHS S10 OD023485
6 · The paper itself

Abstract

Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to

Indexed as

Activities of daily livingNephrologyNutrition related to disease

Identifiers

PMID35059607
PMCPMC8760407
OpenAlexW4200441211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.